Work

A Graded Immune-Cell-Resolved cis-eQTL Mendelian Randomisation Screen Across Systemic Lupus Erythematosus and Related Immune Phenotypes

Year: 2026
Type: article
Abstract: Background: Systemic lupus erythematosus (SLE) is a genetically complex autoimmune disease. Whole-blood expression quantitative trait locus (eQTL) analyses capture average regulatory effects across leukocytes, whereas SLE involves immune processes that depend on cell context. Therefore, a cell-resolved screen requires rigorous verification of instrument identity, allele orientation, and the multiple-testing denominator before biological interpretation. Aims: To conduct an identity-first, immune-cell-resolved cis-eQTL Mendelian randomization (MR) screen across SLE and related immune phenotypes and distinguish statistical signal counts from variant-level, regional, and cross-cell evidence. Study Design: Two-sample summary-data cis-eQTL MR and secondary evidence synthesis using 15 primary human immune-cell types from Database of Immune-Cell Expression (DICE) and eight disease outcomes from FinnGen release 12. Methods: All 19,009 gene-cell-type instruments were audited before outcome testing. Only 6,525 instruments with exact variant identities and concordant DICE effect information were retained for analysis. Wald ratios were calculated for 48,958 outcome-instrument tests, with the Benjamini-Hochberg (BH) procedure applied separately to each outcome to control the false discovery rate (FDR). Both prespecified infection-negative controls were then matched exactly by cell type, gene, and rsID, with each contributing 6,119 tests. For the sensitivity analysis, each chi-square statistic was divided by its outcome-specific genomic control inflation factor (lambda GC), and the BH procedure was reapplied within each outcome. Audited signals were summarized by unique single-nucleotide polymorphisms (SNPs), linkage disequilibrium (LD)-independent index signal, gene-outcome relationship, and MHC location. Regional colocalization, bounded multivariable MR, and Gene Ontology analyses provided additional layers of evidence. Results: The identity-first audit retained 6,525 of 19,009 instruments. Of these, 6,122 matched at least one outcome, whereas 403 did not. Among the 48,958 strict tests, 1,186 rows reached an outcome-specific FDR of less than 0.05, corresponding to 304 genes, 494 SNPs, 868 cell-gene pairs, and 424 gene-outcome relationships. LD auditing resolved 670 outcome-specific lead-SNP records into 639 reference-matched records and 31 separately reported records, yielding 288 LD-independent index signals. The primary SLE analysis identified 55 FDR-significant signals, 23 genes, 29 SNPs, and 11 index signals; 16 of the 23 genes and 6 of the 11 index signals were located in the MHC. The second SLE definition showed a similarly strong concentration of signals in the MHC. Most non-MHC disease signals were associated with rheumatoid arthritis (RA) and autoimmune hypothyroidism (AIH). Lambda GC ranged from 1.17 to 2.03 across disease outcomes. Following outcome-specific lambda adjustment, 483 disease rows remained FDR-significant. The greatest reductions in significant rows occurred for AIH (691-211), RA (213-103), and strict MI (83-11). The negative controls, other sepsis and bacterial infection not otherwise specified (NOS), each matched 6,119 tests and had lambda GC values of 1.06 and 1.08, respectively. No FDR-significant rows were identified for bacterial infection NOS. Conclusion: This revised analysis provides a graded and auditable screening framework rather than a definitive list of SLE risk genes. The primary SLE evidence is concentrated in the 6p21/MHC region, whereas broader non-MHC candidate signals arise predominantly from related immune phenotypes. These findings are hypothesis-generating and require independent replication and experimental validation.
Language: English
Subfield: Genetics
Open Access status: diamond
OpenAlex ID: W7235743602
FWCI:
Cites:
Cited by:
Related to: 10